Research recommendation(s) from an individual piece of guidance
- Guidance:
- Thyroid cancer: assessment and management
- Date issued:
Research recommendations coming out of this guidance
-
Molecular tests: In fine-needle aspiration cytology (FNAC) samples that are adequate but cannot differentiate between benign and malignant samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer?
-
Duration of follow up: What is the clinical and cost effectiveness for different durations of follow up for people with differentiated thyroid cancer who have been treated?
-
Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance compared with surgery?
-
Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who have had surgery and radioactive iodine (RAI), what is the optimal duration of thyroid stimulating hormone suppression?
-
Radioactive iodine: What is the clinical and cost effectiveness of RAI after total or completion thyroidectomy for people with T2 disease and no adverse pathological features?
-
Thyroid peroxidase antibody testing: For people with indeterminate cytopathology, what is the clinical and cost effectiveness of thyroid peroxidase antibody testing?
-
Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound evidence of extensive local spread (T2N1), what is the clinical and cost effectiveness of CT, MRI or F-18 FDG PET-CT scanning, with or without ultrasound, as part of a further staging strategy?
-
External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer?